{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '6.3.12.', 'Clinician Global Impression (CGI) Scales', '51', '6.3.13.', '6-Minute Walk Test (6MWT)', '51', '6.3.14.', 'Pharmacokinetic (PK) Sampling', '52', '6.3.15.', 'Injection Site Reaction (ISR) Assessment', '52', '7.', 'SELECTION AND WITHDRAWAL OF SUBJECTS', '53', '7.1.', 'SPIMM-301 Eligibility', '53', '7.1.1.', 'Subject Inclusion Criteria', '53', '7.1.2.', 'SPIMM-301 Exclusion Criteria', '54', '7.2.', 'PART 2 Eligibility', '55', '7.2.1.', 'PART 2 Subject Continuation Criteria', '55', '7.3.', 'Prohibited Medications', '56', '7.4.', 'Criteria for Subject or Trial Discontinuation', '56', '7.4.1.', 'Discontinuation of Subjects', '56', '7.4.2.', 'Discontinuation of Clinical Site Participation', '57', '7.4.3.', 'Discontinuation of the Trial', '57', '8.', 'INVESTIGATIONAL MEDICINAL PRODUCT MATERIALS AND', 'MANAGEMENT', '58', '8.1.', 'Treatments Administered', '58', '8.1.1.', 'Elamipretide Pen Injector', '58', '8.1.2.', 'Elamipretide Delivery System', '59', '8.2.', 'Materials and Supplies', '60', '8.3.', 'Investigational Medicinal Product Accountability', '60', '8.4.', 'Treatment Compliance', '61', '8.5.', 'Randomization', '61', '8.6.', 'Blinding and Unblinding Procedures', '61', '9.', 'EFFICACY AND SAFETY EVALUATIONS AND APPROPRIATENESS', 'OF MEASUREMENTS', '63', '9.1.', 'Efficacy Endpoints', '63', '9.1.1.', 'Primary Endpoints', '63', '9.1.2.', 'Secondary Endpoints', '63', '9.1.3.', 'Exploratory Endpoints', '63', '9.1.4.', 'Pharmacokinetic (PK) Endpoints', '63', '9.2.', 'Safety Endpoints', '64', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '16']['SPIMM-301 Version 4.0', '15 June 2018', '9.2.1.', 'Adverse Events (AEs)/Adverse Device Effects (ADEs)', '64', '9.3.', 'Pre-Treatment Adverse Events', '65', '9.4.', 'Medical History Conditions', '65', '9.5.', 'Medical and Surgical Procedures', '65', '9.6.', 'Abnormal Laboratory and Other Abnormal Investigational Findings', '65', '9.7.', 'Symptomatic Overdose', '66', '9.8.', 'Serious Adverse Events (SAEs)/Serious Adverse Device Effect (SADEs)', '66', '9.9.', 'Recording of Adverse Events (AEs)/Adverse Device Effects (ADEs)', '66', '9.9.1.', 'Investigator Assessments', '67', '9.9.1.1.', 'Severity', '67', '9.9.1.2.', 'Relationship to the Investigational Medicinal Product (IMP)/Elamipretide', 'Delivery System', '68', '9.9.1.3.', 'Outcome of an Adverse Event (AE)/Adverse Device Effect (ADE)', '68', '9.9.1.4.', 'Investigator Injection Site Reaction (ISR) Assessment', '68', '9.9.2.', 'Adverse Event (AE)/Adverse Device Effect (ADE) Reporting Period', '69', '9.10.', 'Serious Adverse Event (SAE)/Serious Adverse Device Effect (SADE)', 'Expedited Reporting', '69', '9.10.1.', 'Pregnancy and Contraception', '70', '9.10.2.', 'Responsibilities to Regulatory Authorities, Investigators and Ethics', 'Committees', '70', '10.', 'DATA QUALITY ASSURANCE', '72', '10.1.', 'Data Capture System', '72', '11.', 'SAMPLE SIZE AND STATISTICAL METHODS', '73', '11.1.', 'Determination of Sample Size', '73', '11.2.', 'Statistical and Analytical Plans', '73', '11.2.1.', 'General Considerations', '73', '11.2.2.', 'Analysis Populations', '73', '11.2.3.', 'Subject Disposition', '73', '11.2.4.', 'Subject Characteristics', '74', '11.2.5.', 'Efficacy Analyses', '74', '11.2.5.1.', 'Primary Efficacy Endpoints', '74', '11.2.5.2.', 'Secondary Efficacy Endpoints', '74', '11.2.5.3.', 'Exploratory Endpoints', '75', '11.2.5.4.', 'Pharmacokinetic (PK) Endpoints', '75', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '17']\n\n###\n\n", "completion": "END"}